PRESS RELEASE - April 13, 2007

CAVIT SCIENCES, INC. ANNOUNCES PLANS TO HAVE A DRUG MANUFACTURED AND APPLY FOR U.S. FDA APPROVAL

Contact: Colm King
561-544 6988
info@cavitsciences.com

www.CavitSciences.com

Delray Beach, FL, April 13, 2007—Cavit Sciences, Inc. (“Cavit”) (OTCBB: CVIT) today announced its plans to have one of the drugs it tested manufactured and apply for FDA approval.

Testing performed on certain drugs has resulted in patent applications and numerous intellectual property rights which are owned and controlled by Cavit. We intend to have a third party manufacture, per U.S. FDA specifications, one of the drugs we tested, and to apply for U.S. FDA approval for certain cancer and/or viral infection indications. In addition to the current utility rights we own, Cavit will have a source and control of the drug. Due to the safety and effectiveness of the drug’s use outside the U.S., Cavit will apply for fast track or priority approval by the U. S. FDA. Cavit’s board has decided to focus on and to pursue the best course of action in the interest of patients and shareholders.

We have been and are currently negotiating with other drug companies regarding securing rights to their drug compositions. The combination of our current utility rights and the acquisition of composition rights should allow Cavit to develop, market and commercialize these drugs successfully.

Cavit’s plant facilities in Miami are nearly completed and we will be moving in shortly. The facilities will provide ample room for the development of Cavit’s food supplement line. Shareholders and investors will be kept abreast of Cavit’s progress regarding drug development and our food supplement line.

For additional information about this udpate, please visit www.CavitSciences.com.

About Cavit Sciences - Cavit Sciences, Inc. (“Cavit”) is a biotechnology company that has three developed supplement lines with products that enhance, improve, maintain and support the body by beneficially affecting various conditions and is engaged in developing treatments and prevention for cancer, viral infections, opportunistic infections, related diseases and the immune system. New product information and updates will continue to be added to Cavit’s website.

- END -

© 2007 Cavit Sciences